Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced results of a prospective validation study published in the...
A new study demonstrates the ability of Natera's Signatera™ test to assess patient response to immunotherapy in the metastatic setting across...
Noridian, the Medicare Administrative Contractor (MAC) for California-based laboratories, has posted a favorable draft local coverage determination...
A new clinical study shows that Natera's Signatera™ test identified colorectal cancer recurrence up to 16.5 months earlier than radiologic imaging by ...
Natera, Inc. (NASDAQ: NTRA) today announced the publication of a clinical validation study demonstrating that its Signatera™ molecular residual...
Natera, Inc. (NASDAQ: NTRA) today announced that the U.S. Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its...
Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will...
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 5,263,158...
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of...
Natera, Inc. (NASDAQ: NTRA), Cancer Research UK, Imperial College London and the University of Leicester, today announced the publication of results...
Natera, Inc. (NASDAQ: NTRA) Natera, a leader in cell-free DNA testing, today announced plans to commercialize a research-use-only (RUO) service for...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Palmetto MolDx has issued draft local coverage...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA genetic testing, and BGI Genomics Co., Ltd., (300676.SZ), the largest cell-free DNA...
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA, today announced clinical validation study results published in the Journal of Clinical...
Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, today announced that it will webcast a live...
Natera, Inc. (NASDAQ: NTRA), a global leader in non-invasive genetic testing and cell-free DNA, today announced the assignment of two Z-codes for the ...
Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, presented data from two studies this week at ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the assignment of a unique Z-code for the company's kidney...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an agreement with Bristol-Myers Squibb to use Natera's...
Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced the publication of a study demonstrating the value of the...
Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will...
Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing, has appointed Roy Baynes, MB.BCh., M.Med., PhD, FCP, FACP, Chief Medical Officer at...
Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced the pricing of...
Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced the launch of a...
Natera, Inc., (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a research collaboration with the Institut Jules Bordet, an...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.